Oncology Institute names Kim Tzoumakas to board of directors

The Oncology Institute Inc. (NASDAQ: TOI) appointed Kim Tzoumakas to its board of directors effective February 23, 2026, according to a company statement.

Tzoumakas serves as chief executive officer of VytlOne National Pharmacy Services and previously held the CEO position at 21st Century Oncology, where she led an operational turnaround that resulted in the company's sale. She has more than 20 years of executive leadership experience in oncology, pharmacy services and healthcare operations.

Tzoumakas has served on boards of several healthcare companies including SeaSpine, Coherus BioSciences, Ob Hospitalist Group and VytlOne.

"Her deep experience in both oncology and pharmacy services are particularly relevant at this point in TOI's journey as we expand our care delivery model across employed and MSO networks and grow our pharmacy business," said Daniel Virnich, CEO of The Oncology Institute.

The Oncology Institute operates more than 100 clinics and affiliate locations across five states and provides cancer care to approximately 1.9 million patients. The company was founded in 2007 and employs over 180 clinicians.

You May Also Be Interested In

• Coinbase expands board to ten with appointment of Anthony Armstrong
• Prospect Ridge names broadcaster Ellis Martin to board
• Solidion Technology adds three independent directors to its board